ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

Anamorelin Increases Body Mass In Two Global Phase III Trials

October 31, 2014

Seer Data On Cancer Incidence Among Minorities Published

May 10, 1996

FDA Commissioner Mark McClellan tells NCI audience that science is far from eliminating cancer as a threat.

February 6, 2004

NCI May Ask Grantees To Assume Additional Services, Broder Says

November 11, 1994

Also in this 8-page issue: The Cancer Letter wins two awards for its “authoritative examination” of NCI.

June 11, 2004

Fisher and Redmond Subject Of Misconduct Investigation; ORI

May 6, 1994